Community post

Iddo Weiner (BiomX Ltd) and colleagues published a new paper on their nebulized phage cocktail for cystic fibrosis, showing BX004-A met safety endpoints and demonstrated potential reduction in P. aeruginosa sputum burden in first-in-human trial.